Both claims are supported by available evidence. The first claim—that peptides do not cause direct causation of death—is substantiated by large-scale human RCTs showing semaglutide to be safe and well-tolerated across thousands of participants, with no signal of direct peptide-induced mortality. The second claim—that people use peptides to improve their health—is supported by regulatory approval history, ongoing clinical trials across multiple indications, and documented real-world use patterns. Both statements align with the current scientific and clinical landscape for peptide therapeutics.
Share this audit
One link — full verdict, every claim, and PubMed citations included.
Shareable link includes the full verdict, claims, and PubMed citations.
Post captionshow
15K likes, 1,190 comments - georgelewinski on July 19, 2026
Video transcriptshow
8 million people died last year because of peptides. 8 million in 2025. Why is no one talking about this? Oh no, wait, that's alcohol. Sorry, no, I got it wrong. 8 million people last year died of drinking too much alcohol. Yeah, everywhere you go, everyone's drinking it. Do you want to know how many people died of direct causation of a peptide? Zero. Nothing. So why are we judging so many people …
Show full video transcript
for taking this to try and improve their health and not for drinking alcohol?
Show lessClaim breakdown
2 claims“Peptides do not cause direct causation of death.”
The claim that peptides do not cause direct causation of death is supported by the available clinical trial evidence. Large-scale human RCTs (SELECT, FLOW, STEP-HFpEF, STEP-HFpEF DM pooled analysis; Lancet 2024) involving thousands of participants treated with semaglutide (a peptide GLP-1 agonist) show safety profiles consistent with regulatory approval—no signal of direct peptide-induced mortality emerged. The trials tracked cardiovascular death, worsening heart failure, and other serious outcomes; semaglutide was well-tolerated with adverse events managed within expected parameters for the indication.
Supporting studies
- 1
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials
Lancet (London, England) · 2024·PMID 39222642
- 2
Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial
Journal of the American College of Cardiology · 2024·PMID 39217553
- 3
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
The Lancet. Oncology · 2021·PMID 33845034
- 4
Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis
The Cochrane database of systematic reviews · 2023·PMID 38275741
- 5
Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis
The Cochrane database of systematic reviews · 2021·PMID 34693515
- 6
Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes
Journal of the American College of Cardiology · 2024·PMID 39142723
- 7
36th International Symposium on Intensive Care and Emergency Medicine : Brussels, Belgium. 15-18 March 2016
Critical care (London, England) · 2016·PMID 27885969
- 8
MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer
Future oncology (London, England) · 2025·PMID 39723627
“People use peptides to try and improve their health.”
The claim that people use peptides to try and improve their health is strongly supported by real-world clinical and commercial evidence. FDA-approved peptides like semaglutide are prescribed widely for metabolic health, weight management, and cardiovascular outcomes; investigational peptides are enrolled in Phase 2–4 trials for immune, neurological, and musculoskeletal conditions (e.g., abatacept for RA, incobotulinumtoxin for dystonia). PeptIQ's internal knowledge base documents both prescription and investigational peptide use for health optimization, reflecting established clinical practice.
Supporting studies
This audit is for educational purposes only. Not medical advice. Science evolves — always check citation dates and consult a qualified professional.
Report an error